IL110309A0 - A method of protecting against neuron loss - Google Patents

A method of protecting against neuron loss

Info

Publication number
IL110309A0
IL110309A0 IL11030994A IL11030994A IL110309A0 IL 110309 A0 IL110309 A0 IL 110309A0 IL 11030994 A IL11030994 A IL 11030994A IL 11030994 A IL11030994 A IL 11030994A IL 110309 A0 IL110309 A0 IL 110309A0
Authority
IL
Israel
Prior art keywords
vitamin
compound
neuron loss
against neuron
protect against
Prior art date
Application number
IL11030994A
Other languages
English (en)
Original Assignee
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kentucky Res Found filed Critical Univ Kentucky Res Found
Publication of IL110309A0 publication Critical patent/IL110309A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • Moving Of Heads (AREA)
IL11030994A 1993-07-15 1994-07-13 A method of protecting against neuron loss IL110309A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9197693A 1993-07-15 1993-07-15

Publications (1)

Publication Number Publication Date
IL110309A0 true IL110309A0 (en) 1994-10-21

Family

ID=22230588

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11030994A IL110309A0 (en) 1993-07-15 1994-07-13 A method of protecting against neuron loss

Country Status (10)

Country Link
US (1) US5939407A (ja)
EP (1) EP0710112B1 (ja)
JP (1) JPH09507830A (ja)
AT (1) ATE209921T1 (ja)
AU (1) AU7333694A (ja)
CA (1) CA2167171C (ja)
DE (1) DE69429351T2 (ja)
ES (1) ES2166377T3 (ja)
IL (1) IL110309A0 (ja)
WO (1) WO1995002409A2 (ja)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1011683A4 (en) * 1997-05-22 2003-06-11 Cephalon Inc VITAMIN D ANALOGS AND THEIR EFFECTS ON NEURONS
NZ507449A (en) * 1998-05-15 2003-08-29 Univ Leland Stanford Junior Glucocorticoid receptor antagonists for the treatment of dementia
AU6137801A (en) * 2000-05-09 2001-11-20 Childrens Medical Center Method and composition for the treatment of angiogenesis
US7858602B2 (en) * 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
EP1330467B1 (en) * 2000-11-03 2007-05-02 Washington University Modified, hydroxy-substituted aromatic structures having cytoprotective activity
AU2002228891A1 (en) * 2000-11-17 2002-05-27 Washington University Cytoprotective estrogen derivatives
AU2002303652B2 (en) * 2001-05-04 2006-08-31 Corcept Therapeutics, Inc. Methods for treating delirium using glucocorticoid receptor-specific antagonists
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20050192255A1 (en) * 2003-07-30 2005-09-01 Jin Tian Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
WO2005116047A2 (en) * 2004-05-27 2005-12-08 Migenix Corp. 2-substituted 17-imino estrogen compounds for cytoprotection
AU2006251832A1 (en) * 2005-05-27 2006-11-30 Queen's University At Kingston Treatment of protein folding disorders
JP2007023010A (ja) * 2005-07-19 2007-02-01 Toshiro Azegami 閉経後のホルモンバランス調整及びパーキンソン症の予防改善目的の経口組成物
HUE035852T2 (en) * 2006-04-03 2018-05-28 Accera Inc Use of ketogen compounds to treat memory decline
EP2167098B1 (en) * 2007-06-11 2018-09-05 University Of Southern California Allopregnanolone in a method for enhancing neurological function (alzheimer disease)
US20100204192A1 (en) 2007-06-11 2010-08-12 University Of Sourthern California Agents, compositions and methods for enhancing neurological function
US20110306579A1 (en) * 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
EP2363119A1 (fr) * 2010-03-05 2011-09-07 Centre Hospitalier Universitaire d'Angers Nouvelle composition pharmaceutique utile pour le traitement des personnes affectées par des maladies neurodégénératives ou neurovasculaires
FR2965178B1 (fr) * 2010-09-29 2012-10-05 Sebastien Lasnier Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer
ES2951664T3 (es) * 2011-09-08 2023-10-24 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
EP3932932A1 (en) 2013-03-13 2022-01-05 Sage Therapeutics, Inc. Neuroactive steriods and methods of use thereof
US20140296190A1 (en) * 2013-03-27 2014-10-02 Dsm Ip Assets B.V. Marketing the use of 25-hydroxyvitamin d3 to enhance cognition
CN105208878A (zh) * 2013-03-27 2015-12-30 帝斯曼知识产权资产管理有限公司 25-羟基维生素d3用于增强执行功能的用途
ES2536256B2 (es) 2013-11-20 2016-02-01 Universidade De Santiago De Compostela Análogos de vitamina d con interés farmacéutico
EP4306114A1 (en) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA42409A (fr) 2015-07-06 2018-05-16 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
RU2021100620A (ru) 2015-07-06 2021-01-29 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
MY197698A (en) 2015-07-06 2023-07-06 Sage Therapeutics Inc Oxysterols and methods of use thereof
LT3436022T (lt) 2016-04-01 2022-06-27 Sage Therapeutics, Inc. Oksisteroliai ir jų panaudojimo būdai
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (es) 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
CN110023323A (zh) 2016-09-30 2019-07-16 萨奇治疗股份有限公司 C7取代的氧固醇及其作为nmda调节剂的方法
MA46565A (fr) 2016-10-18 2019-08-28 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
CA3041088C (en) 2016-10-18 2024-05-21 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US20230218581A1 (en) 2020-04-24 2023-07-13 The Johns Hopkins University Compositions and methods comprising dendrimers and therapeutic agents
WO2023028554A1 (en) 2021-08-25 2023-03-02 Neuraly, Inc. Glp-1r agonists for use in a treatment of neurological impairment associated with viral infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63104926A (ja) * 1986-10-21 1988-05-10 Teijin Ltd 老年性痴呆症治療又は予防剤
FR2639225B1 (fr) * 1988-11-21 1993-05-21 Centre Nat Rech Scient Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
US4957909A (en) * 1989-05-04 1990-09-18 American Home Products Corporation Benzobicycloalkane derivatives as anticonvulsant neuroprotective agents
US5089517A (en) * 1990-08-03 1992-02-18 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection by indolactam v and derivatives thereof
US5168103A (en) * 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
US5196421A (en) * 1991-06-05 1993-03-23 Eli Lilly And Company Excitatory amino acid receptor antagonists in methods for the use thereof
US5153196A (en) * 1991-06-05 1992-10-06 Eli Lilly And Company Excitatory amino acid receptor antagonists and methods for the use thereof

Also Published As

Publication number Publication date
ES2166377T3 (es) 2002-04-16
AU7333694A (en) 1995-02-13
US5939407A (en) 1999-08-17
CA2167171A1 (en) 1995-01-26
WO1995002409A2 (en) 1995-01-26
DE69429351T2 (de) 2002-05-23
EP0710112B1 (en) 2001-12-05
CA2167171C (en) 2007-04-24
WO1995002409A3 (en) 1995-04-27
JPH09507830A (ja) 1997-08-12
DE69429351D1 (de) 2002-01-17
ATE209921T1 (de) 2001-12-15
EP0710112A1 (en) 1996-05-08

Similar Documents

Publication Publication Date Title
IL110309A0 (en) A method of protecting against neuron loss
CA2202879A1 (en) Calcium receptor-active compounds
PT1156043E (pt) Drogas que aumentam as respostas sinapticas mediadas por receptores de ampa
AU3990797A (en) Sustained release formulation
MD895B2 (ro) Preparat sinergetic şi procedeu de distrugere selectivă a buruienilor
EP0744942A4 (en) HYDROGEL FORMULATION WITH CONTROLLED RELEASE
CA2117532A1 (en) Method of inhibiting carcinogenesis by treatment with dehydropiandrosterone and analogs thereof
AU1876788A (en) Methylene phosphonoalkylphosphinates, pharmaceutical compositions , and methods for treating abnormal calcium and phosphate metabolism
GB2223403B (en) Inositoltrisphosphate for the treatment of disorders related to transplantation
HU9301578D0 (en) Fungicidal preparatives containing 1-aryl-3-(3,4-dihydro-4-oxo-3-quinazolinyl)-urea as active substance
NO994395L (no) Stabilt, fast preparat som inneholder vitamin D3 og trikalsiumfosfat
MX9705806A (es) Forma farmaceutica destinada a la cesion de colagenasa en heridas, y procedimiento para su elaboracion.
DE69314463T2 (de) Hautregenerierende kosmetische zusammensetzung
BR9812144A (pt) Antagonistas da atividade de androgen como terapias para anorexia, anorexia nervosa e distúrbios caracterizados por uma condiçao de baixo peso patológica
WO1990001321A3 (en) Method for treating and preventing loss of bone mass
BR9811829A (pt) Processos para fumegação do solo contendo organismos deletérios controlando ao mesmo tempo a fitotoxicidade, e, para controlar organismos deletérios no solo
BR9707770C1 (pt) Tifluzamida com eficácia aperfeiçoada
DK0575974T3 (ja)
ES2078319T3 (es) Composiciones que contienen inhibidores de aldosa reductasa para el tratamiento de ulceras.
IL96506A0 (en) Transdermal system for administering pharmaceutical compounds under ph control
MX9302986A (es) Medicamento que contiene metrifonato y procedimiento para su preparacion
DE69628430D1 (de) Verwendung von lactoferrin zur prävention des nachoperativen astigmatismus
ES8404182A1 (es) Un metodo de prepara el enantiomero (+) s de secoverin
HU9402698D0 (en) Pharmaceutical composition for treating climacteric osteoporosis
DE69801907D1 (de) Verwendung von 9,10-secocholesta-5,7,10(19)-trien-1,3-ol (alfacalcidol)